Drug Trial Radar · NCT02607930
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Last checked: Nov 19, 2026Latest source record: Mar 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
631
Actual
Start
Nov 13, 2015
Primary completion
May 9, 2017
Study completion Jul 2, 2021
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) in HIV-1 infected, antiretroviral treatment naive-adults.
Conditions
- HIV-1 Infection
Interventions
ABC/DTG/3TCDrug
600/50/300 milligrams (mg) tablets administered orally, once daily
B/F/TAFDrug
50/200/25 mg tablets administered orally, once daily, without regard to food
ABC/DTG/3TC PlaceboDrug
Tablets administered orally, once daily
B/F/TAF PlaceboDrug
Tablets administered orally, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot AlgorithmTime frame: Week 48
Locations
121 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Spectrum Medical Group
Phoenix, Arizona
Pueblo Family Physicians
Phoenix, Arizona
Kaiser Permanente Medical Center
Los Angeles, California
Ruane Clinical Research Group, Inc.
Los Angeles, California
Anthony Martin Mills MD A Medical Corporation, DBA Mills Clinical Research
Los Angeles, California
Alameda Health System- Highland Hospital
Oakland, California
University of California Davis
Sacramento, California
Kaiser Permanente Medical Group
Sacramento, California
La Playa Medical Group
San Diego, California
Kaiser Permanente
San Francisco, California
Kaiser Permanente
San Leandro, California
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Apex Research
Denver, Colorado
Whitman-Walker Institute
Washington D.C., District of Columbia
Providence Hospital - DC
Washington D.C., District of Columbia
Capital Medical Associates
Washington D.C., District of Columbia
Medical Faculty Associates
Washington D.C., District of Columbia
Therafirst Medical Center
Fort Lauderdale, Florida
Gary J. Richmond, M.D., P.A.
Fort Lauderdale, Florida
Midway Immunology and Research Center
Ft. Pierce, Florida
AHF Kinder Medical Group
Miami, Florida
Site not named
Miami, Florida
Orlando Immunology Center
Orlando, Florida
AIDS Healthcare Foundation-Miami Beach
Pensacola, Florida
St. Joseph's Comprehensive Research Institute
Tampa, Florida
AIDS Research and Treatment Center of the Treasure Coast
Vero Beach, Florida
Triple O Research Institute PA
West Palm Beach, Florida
Emory University
Atlanta, Georgia
Atlanta Infectious Disease Group PC
Atlanta, Georgia
Aids Research Consortium of Atlanta Inc
Atlanta, Georgia
Augusta University
Augusta, Georgia
Infectious Disease Specialists of Atlanta
Decatur, Georgia
Chatham County Health Department
Savannah, Georgia
Indiana CTSI Clinical Research Center
Indianapolis, Indiana
Louisiana State University Health Sciences Center
New Orleans, Louisiana
Baystate Medical Center
Springfield, Massachusetts
Be Well Medical Center
Berkley, Michigan
Henry Ford Health System
Detroit, Michigan
Hennepin County Medical Center
Minneapolis, Minnesota
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.